Mizojiri K, Okabe H, Sugeno K, Esumi Y, Takaichi M, Tsutsumi S, Harada T, Miyoshi R, Inaba A
New Drug Research Laboratories, Shionogi & Co., Ltd., Osaka, Japan.
Arzneimittelforschung. 1997 Feb;47(2):195-200.
4-[(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl]benzoic acid (CAS 94497-51-5, Am-80) is a new synthetic retinoid which has been shown to have a potent topical antisporiatic activity. The accumulation characteristics of Am-80 were examined in rats after a single and consecutive subcutaneous administration of 14C-labeled Am-80 once a day for 24 days, at a daily dose of 0.2 mg/kg. As compared with the single administration, Tmax (1-2 h) and Cmax (about 50 ng eq./ml) of the blood radioactivity were not altered markedly after the consecutive administration. During the daily subcutaneous dosing, the blood level of radioactivity at 24 h after each dosing was also very low. These findings suggested that accumulation in the blood was low after long term consecutive administration of Am-80. The plasma levels of total radioactivity and the proportion of unchanged Am-80 to the total plasma radioactivity, being about 80% at 2 h after administration, and plasma elimination half-life of Am-80, being approximately 3 h, appeared to be hardly affected by the consecutive administration. The cumulative excretion of radioactivity at 168 h after the final dosing was 6.7% and 89.1% in the urine and feces, respectively. The radioactivity remaining in the carcass at this time was about 3% of the total dose. The excretion profile was not altered by the consecutive administration. In most tissues, the concentration of radioactivity at 24 h after each dose reached a steady-state within 24 doses. At 2 h after the consecutive administration for 24 days, the highest concentration of radioactivity was found in the liver followed by the adrenal gland. Accumulation and delayed elimination of radioactivity in most tissues, especially in the adrenal gland, fat, skin and epididymis, were evidently observed as predicted from the previous study where 14C-Am-80 was administered at a dose of 1 mg/kg. The profile of accumulation and retention of radioactivity after the consecutive administration may be considered as a common characteristic of retinoids, such as etretinate.
4-[(5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基)氨基甲酰基]苯甲酸(CAS 94497-51-5,Am-80)是一种新型合成类视黄醇,已显示具有强大的局部抗孢子活性。在大鼠中,每天皮下注射一次14C标记的Am-80,连续给药24天,每日剂量为0.2 mg/kg,之后检测Am-80的蓄积特征。与单次给药相比,连续给药后血药放射性的达峰时间(1 - 2小时)和峰浓度(约50 ng当量/毫升)无明显改变。在每日皮下给药期间,每次给药后24小时的血药放射性水平也非常低。这些发现表明,长期连续给予Am-80后,血液中的蓄积量较低。给药后2小时血浆总放射性水平以及未变化的Am-80占血浆总放射性的比例约为80%,Am-80的血浆消除半衰期约为3小时,连续给药似乎对其影响不大。末次给药后168小时,放射性在尿液和粪便中的累积排泄率分别为6.7%和89.1%。此时残留在 carcass中的放射性约为总剂量的3%。连续给药未改变排泄情况。在大多数组织中,每次给药后24小时的放射性浓度在24次给药内达到稳态。连续给药24天后2小时,放射性浓度最高的组织是肝脏,其次是肾上腺。正如之前以1 mg/kg剂量给予14C-Am-80的研究所预测的那样,在大多数组织中,尤其是肾上腺、脂肪、皮肤和附睾中,明显观察到放射性的蓄积和延迟消除。连续给药后放射性的蓄积和滞留情况可被视为类视黄醇(如阿维A酯)的共同特征。